Ceftriaxone Injectable Antibiotic Recalled Nationwide for Sterility Assurance Deficiency
Astral SteriTech's 66,125-vial ceftriaxone injection is being recalled nationwide due to lack of assurance of sterility in manufacturing. The product is distributed across the United States.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall without any reported illnesses or hospitalizations. The hazard involves inadequate sterility assurance for an injectable medication, which meets the rubric criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Astral SteriTech Private Ltd. is recalling 66,125 vials of Ceftriaxone for Injection, USP 250 mg per vial, an injectable antibiotic manufactured for Xellia Pharmaceuticals USA, LLC. The product has been distributed nationwide within the United States. The recall has been issued due to lack of assurance of sterility in the manufacturing process.
Ceftriaxone is administered by injection to treat bacterial infections. As an injectable medication, it must be sterile to be safe for use. The recall addresses a deficiency in manufacturing quality assurance controls that verify sterility of the product.
Healthcare providers and pharmacies should stop distribution of affected vials and quarantine them. Patients who have received injections of this recalled product should consult their healthcare provider if they have concerns about their medication.
The recalled product
- Product
- Ceftriaxone for Injection, USP 250 mg per vial, Rx only, Manufactured for: Xellia Pharmaceuticals USA, LLC, Buffalo Grove, IL 60089, NDC 70594-094-02
- Manufacturer
- Astral SteriTech Private Ltd.
- Category
- Drug — Injectable Antibiotic
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27